Cancer/testis antigen 1 (127-136)

Cancer/testis antigen 1 (127-136) is a synthetic peptide fragment derived from the well-characterized cancer/testis antigen family, specifically representing amino acid residues 127 to 136 of the parent protein. As a member of the cancer/testis antigen group, this peptide is notable for its restricted expression in normal adult tissues and prevalent upregulation in various malignancies, making it a valuable molecular tool in oncology and immunology research. Its well-defined sequence and immunogenic properties have positioned it as a critical reagent in studies exploring tumor-associated antigens, T cell recognition, and antigen presentation. The biochemical specificity and relevance of this peptide support its widespread use in fundamental and translational research settings.

Epitope mapping: The 127-136 peptide fragment serves as a precise epitope for characterizing T cell responses against cancer/testis antigens. Researchers utilize it in assays such as ELISPOT, intracellular cytokine staining, and tetramer analysis to delineate the specificity and magnitude of CD8+ cytotoxic T lymphocyte responses. This application is essential for understanding the immunogenic landscape of tumor antigens, dissecting mechanisms of immune recognition, and identifying potential targets for immunotherapeutic interventions.

Immunogenicity assessment: The peptide is frequently employed in in vitro stimulation assays to evaluate the immunogenic potential of cancer/testis antigens. By exposing peripheral blood mononuclear cells or tumor-infiltrating lymphocytes to the peptide, investigators can assess activation markers, cytokine production, and proliferation. These studies inform the design of antigen-specific vaccines and provide insights into the natural immune repertoire capable of recognizing tumor-associated epitopes.

Antigen presentation studies: The defined sequence of this peptide enables its use in examining the molecular mechanisms of antigen processing and presentation via major histocompatibility complex (MHC) class I molecules. By loading the peptide onto antigen-presenting cells, researchers can investigate the efficiency of peptide-MHC binding, the stability of peptide complexes, and the downstream activation of T cells. Such studies are fundamental for optimizing antigen delivery strategies and understanding immune evasion by tumors.

Peptide-based screening: Laboratories employ the 127-136 peptide in high-throughput screening platforms to identify and validate T cell receptors (TCRs) or monoclonal antibodies with specificity for cancer/testis antigens. This approach accelerates the discovery of novel immunotherapeutic candidates and supports the engineering of TCRs or antibody-based modalities with enhanced specificity and affinity for tumor-associated epitopes.

Functional analysis of immune modulation: The peptide is also utilized in functional assays to investigate the regulatory mechanisms that influence anti-tumor immune responses. By incorporating it into co-culture systems or immune checkpoint studies, scientists can probe the effects of immune modulators, such as checkpoint inhibitors or cytokines, on antigen-specific T cell activity. These experiments contribute to a deeper understanding of how the tumor microenvironment shapes immune surveillance and response to immunotherapies.

1. Store-operated Ca2+ entry sustains the fertilization Ca2+ signal in pig eggs

2. C-Peptide replacement therapy and sensory nerve function in type 1 diabetic neuropathy

3. SERS spectrum of the peptide thymosin‐β4 obtained with Ag nanorod substrate

4. Cell-based adhesion assays for isolation of snake venom’s integrin antagonists

5. Adipose tissue is a key organ for the beneficial effects of GLP-2 metabolic function